Compare Bristol-Myers Squibb Co (BMY) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Kohl's Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B), while Kohl's Corporation trades at $19.24 (market cap $2.10B). The key difference: Bristol-Myers Squibb Co is far larger — about 61.9× Kohl's Corporation's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | KSS | |
|---|---|---|
Market Cap | $129.94B | $2.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $24.71 |
52-Week Low | $42.60 | $11.72 |
Enterprise Value | $163.92B | $8.20B |
Dividend Yield | 3.96% | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
